Alpha Tau Medical

20/04/2026

A Hidden Gem in Biotech: The Untold Story of Israeli Imagination and Reinvention that Could Revolutionize Cancer Treatment

What happens when a century-old, Nobel Prize-winning discovery gathers dust for over a decade, only to resurface as one of Israel's most promising biotech companies?

In a compelling Independence Day feature, Yedioth Ahronoth spotlights an Israeli clinical-stage oncology company that has already treated hundreds of cancer patients worldwide.

The story isn't just about groundbreaking science. It's about a pivotal decision that almost never happened, born from a chance meeting that changed everything. It's a tale of years spent navigating complex battles and near total failure before the breakthrough moment finally arrived. At the center of it all stands a visionary Israeli CEO who walked away from a successful exit to pursue an audacious mission that most would have abandoned long ago.

What makes this story truly remarkable is how Israeli innovation in precision oncology is potentially reshaping global cancer care from Jerusalem itself, while simultaneously building manufacturing infrastructure across continents towards scaling treatments to patients worldwide. The article reveals the untold challenge of reviving a technology that the scientific community had essentially written off as impractical.

Read the full interview to discover the strategy, resilience, and conviction and chutzpah (hallmark Israeli characteristics) behind one of biotech's most compelling comeback stories. Learn how a forgotten scientific principle became the foundation for a new way for the world to approach one of medicine's greatest challenges.

Read the full article in the link provided in the comments

01/04/2026

Passover Sameach from all of us at Alpha Tau ✨

31/03/2026

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

“The acceptance of this abstract for an oral presentation at DDW is an important milestone for Alpha Tau” stated U*i Sofer, CEO of Alpha Tau, “It reflects the growing recognition of the potential of our technology to address this devastating disease."

Jerusalem, March 31, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been ...

30/03/2026

At Alpha Tau Medical, innovation drives us every day but once a year, we pause everything for something even more meaningful.

In the days leading up to Passover, our teams step away from their labs, meetings, code, and development. Pens are set down, computers are closed, pipettes and vials are put aside, and even SolidWorks takes a break. For a few special hours, we come together not as engineers, researchers, or professionals but as a community.

Together, we volunteer.

As part of our annual קמחא דפסחא (Kimcha D’Pischa) tradition, Alpha Tau employees pack boxes filled with food and essential items for families in need, ensuring they can celebrate Passover with dignity. Because for us, Passover is more than a holiday, it’s a time to give back, to care, and to stand beside those who need it most.

This year, as in years past, we are honored to partner with Reyim (רעים) - a remarkable nonprofit led by passionate young volunteers. “Reyim” in Hebrew is a meaningful word -represents deep friendship, true connection, and shared destiny. Values that resonate deeply with us.

Their mission is simple yet powerful:
Every person deserves dignity, food security, and a supportive community.
Through their work, they provide food baskets, companionship for the elderly, and meaningful support for families who need to know they are not alone.
We are proud and grateful to stand alongside Reyim in this mission and wish everyone a happy and meaningful Passover.

Special thanks to Dolev Sofer and Amit Ginou for organizing this unique event

16/03/2026

to Present at March Virtual Small Cap Conference

Our CFO, Mr. Raphi Levy, will be available for 1x1 investor meetings at the conference.

Please reach out to your Sidoti representative to schedule.

Jerusalem, March 16, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18 - 19, 2026.Mr. Levy...

09/03/2026

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment.

Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial.

$76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation.

Read the full PR below:

https://www.alphatau.com/single-post/alpha-tau-announces-full-year-2025-financial-results-and-provides-corporate-update

24/02/2026

Alpha Tau Medical Receives Japanese Marketing Approval for ® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

https://lnkd.in/dNhemP6c

05/02/2026

Today at Alpha Tau Medical, we took some time to come together to mark one year since the passing of the late Professor Itzhak Kelson, a brilliant scientist whose vision helped bring the Alpha Dart® technology to life.

Since his passing, his influence has not faded; it has only grown stronger in the work we do every day. Itzhak’s scientific legacy continues to guide our innovation, but it is his character - warm, humble, endlessly curious, and full of gentle humor - that remains closest to our hearts and that is most deeply cherished.

Shai Lax, materials engineer, relayed some beautiful Jewish teachings, connecting them to Itzhak, to honor and elevate the moment.

Yadin Cohen, Head of Physics, spoke movingly about his relationship with Itzhak - about mentorship, collaboration, and the quiet brilliance that defined him. His words reminded us that Itzhak’s greatest impact was not only in the technologies he helped create, but in the people he encouraged, supported, and believed in.

Niv Golan played a lovely piece of music by Arik Einstein, a small but meaningful gesture that evoked Itzhak’s characteristic warmth and personality and love of culture.

Professor Kelson was more than a scientist. He was a kind friend and devoted mentor, a colleague whose presence made every conversation brighter and lighter. His contributions to science and physics are lasting and profound, but his legacy at Alpha Tau is equally defined by empathy, integrity, joy, and humor.

Today, we remember him with gratitude. As we continue to work hard to carry forward the legacy of his important work to bring hope to cancer patients around the world, we pause and reflect on where we came from, how far we’ve come, and how inspired we are to keep moving.

04/02/2026

On , we stand with patients and their families as we continue to pursue our mission to advance worldwide and to offer hope for those who need it most.

02/02/2026

New Horizons for Recurrent Skin Cancer Treatment
As featured in : "Less Invasive Skin Cancer Treatments"

Finding the right treatment for recurrent cutaneous squamous cell carcinoma ( ) can be a challenging journey, especially when traditional surgical options may not be the ideal path for every patient. For many patients, the challenge is finding a treatment that delivers clinical effectiveness while preserving quality of life, particularly in sensitive or previously treated areas.

Alpha Tau Medical is proud to spotlight the work of Dr. Jacob Beer, who is leading a pivotal clinical trial featuring our innovative ® technology. This approach uses highly localized, designed to target tumors from within while potentially minimizing impact on surrounding healthy tissue.

Through the clinical trial, we are working to expand access to new treatment pathways for patients with recurrent cSCC who may have limited options. At the same time, we aim to equip clinicians with an additional, precision-focused tool to address complex cases and advance patient-centered cancer care.

Alpha DaRT treatment for recurrent cSCC is currently available only as part of a clinical trial in the US.

For more information, please contact info@alphatau.com

Not to be the cloud in our sunny Florida sky, but it’s well known that our state has some of the highest rates of skin cancer in the country. Our year-round sunshine and strong ultraviolet (UV) exposure put residents at elevated risk. But skin cancer, particularly recurrent skin cancer, isn’t ju...

29/01/2026

Alpha Tau Medical Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal trial as well as trials in cancers of internal organs including the pancreas and brain -

- Ramping U.S. manufacturing for commercial readiness -

To see the full letter, please read:

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

20/01/2026

Alpha Tau Medical at 2026 - Advancing Combination Therapy in Head and Neck Cancer

Following the release of promising interim clinical trial data studying the Alpha DART® in combination with pembrolizumab as a treatment for locally advanced and metastatic , Alpha Tau continues to see strong interest in this clinical program. Prof. Aron Popovtzer, MD, Chair of the Sharett Institute of Oncology at Hadassah Medical Center and lead investigator of the study, will be attending the Multidisciplinary Head and Neck Cancers Symposium (MHNCS), February 19–21, 2026, in Palm Desert, California.

Prof. Popovtzer will be available to share insights and discuss potential collaboration opportunities related to the Alpha DART and pembrolizumab combination approach. We welcome meetings with colleagues interested in learning more. Please direct message us or email info@alphatau.com to connect.